164 related articles for article (PubMed ID: 12416736)
1. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
2. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
3. Biological characteristics and prognostic value of in vitro three-drug resistance to prednisolone, L-asparaginase, and vincristine in childhood acute lymphoblastic leukemia.
Hongo T; Yamada S; Yajima S; Watanabe C; Fujii Y; Kawasaki H; Yazaki M; Hanada R; Horikoshi Y
Int J Hematol; 1999 Dec; 70(4):268-77. PubMed ID: 10643153
[TBL] [Abstract][Full Text] [Related]
4. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
5. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia.
Den Boer ML; Harms DO; Pieters R; Kazemier KM; Gobel U; Körholz D; Graubner U; Haas RJ; Jorch N; Spaar HJ; Kaspers GJ; Kamps WA; Van der Does-Van den Berg A; Van Wering ER; Veerman AJ; Janka-Schaub GE
J Clin Oncol; 2003 Sep; 21(17):3262-8. PubMed ID: 12947061
[TBL] [Abstract][Full Text] [Related]
6. In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
Ramakers-van Woerden NL; Pieters R; Hoelzer D; Slater RM; den Boer ML; Loonen AH; Harbott J; Janka-Schaub GE; Ludwig WD; Ossenkoppele GJ; van Wering ER; Veerman AJ;
Med Pediatr Oncol; 2002 Jun; 38(6):379-86. PubMed ID: 11984797
[TBL] [Abstract][Full Text] [Related]
7. Comparison of prognostic value of in vitro drug resistance and bone marrow residual disease on day 15 of therapy in childhood acute lymphoblastic leukemia.
Styczynski J; Piatkowska M; Jaworska-Posadzy A; Czyzewski K; Kubicka M; Kolodziej B; Kurylo-Rafinska B; Debski R; Pogorzala M; Wysocki M
Anticancer Res; 2012 Dec; 32(12):5495-9. PubMed ID: 23225457
[TBL] [Abstract][Full Text] [Related]
8. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM-90 and CoALL-05-92.
Schlieben S; Borkhardt A; Reinisch I; Ritterbach J; Janssen JW; Ratei R; Schrappe M; Repp R; Zimmermann M; Kabisch H; Janka-Schaub G; Bartram CR; Ludwig WD; Riehm H; Lampert F; Harbott J
Leukemia; 1996 Jun; 10(6):957-63. PubMed ID: 8667652
[TBL] [Abstract][Full Text] [Related]
9. [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-06-97].
Janka-Schaub GE; Harms DO; den Boer ML; Veerman AJ; Pieters R
Klin Padiatr; 1999; 211(4):233-8. PubMed ID: 10472556
[TBL] [Abstract][Full Text] [Related]
10. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
11. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
[TBL] [Abstract][Full Text] [Related]
12. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
13. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group.
Schrappe M; Reiter A; Ludwig WD; Harbott J; Zimmermann M; Hiddemann W; Niemeyer C; Henze G; Feldges A; Zintl F; Kornhuber B; Ritter J; Welte K; Gadner H; Riehm H
Blood; 2000 Jun; 95(11):3310-22. PubMed ID: 10828010
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
15. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study.
Jabbour E; Kantarjian H; Ravandi F; Thomas D; Huang X; Faderl S; Pemmaraju N; Daver N; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Yin CC; Khoury JD; Jorgensen J; Estrov Z; Bohannan Z; Konopleva M; Kadia T; Jain N; DiNardo C; Wierda W; Jeanis V; O'Brien S
Lancet Oncol; 2015 Nov; 16(15):1547-1555. PubMed ID: 26432046
[TBL] [Abstract][Full Text] [Related]
16. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: durable responses to chemotherapy associated with low initial white blood cell counts.
Ribeiro RC; Broniscer A; Rivera GK; Hancock ML; Raimondi SC; Sandlund JT; Crist W; Evans WE; Pui CH
Leukemia; 1997 Sep; 11(9):1493-6. PubMed ID: 9305603
[TBL] [Abstract][Full Text] [Related]
17. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
18. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
[TBL] [Abstract][Full Text] [Related]
19. Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.
Leahey AM; Bunin NJ; Belasco JB; Meek R; Scher C; Lange BJ
Med Pediatr Oncol; 2000 May; 34(5):313-8. PubMed ID: 10797352
[TBL] [Abstract][Full Text] [Related]
20. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]